|Day Low/High||56.33 / 59.74|
|52 Wk Low/High||11.57 / 116.75|
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Clovis Oncology Inc , where a total of 10,313 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.4% of CLVS's average daily trading volume over the past month of 1.4 million shares.
The number of new 12-month highs has climbed to 240.
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.
A new treatment has been approved by the FDA for treatment of ovarian cancer. The treatment is made by Clovis Oncology.
Clovis will market the new drug under the brand name Rubraca.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Clovis Oncology Inc.
Investors in Clovis Oncology Inc saw new options become available this week, for the July 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Clovis Oncology, Inc.
In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $33.14, changing hands for $33.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder...
But, Jim Cramer says, he thinks Elon Musk's solar shingles look really nice.
Investors need to sift through the confusing crosswinds hitting the market, Jim Cramer says.
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick Mahaffy, the Company's President and CEO, will present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8, at 1:00pm MST.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.
A day after winning approval for a cancer drug, Merck posts earnings and sales that beat consensus estimates.
Jim Cramer says he doesn't like solar companies, but ICE is cool. Cable stocks, he says, are underrated.
Staying home is the new going out, and these companies are profiting, Cramer says.
Many traders follow trends, but these can change quickly, sending a stock plummeting. There are signals that will help a trader know how to avoid this type of pattern.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
Clovis Oncology (CLVS) gave an update on a clinical trial for its rucaparib drug on Friday, showing its candidate might be inferior to competitors.
Takeover speculation that had fueled the recent rise in Clovis' stock price looks to be subsiding.
Clovis Oncology (NASDAQ:CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.